Analyzing T-cell Repertoire in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplant
Characterization of T-cell Repertoire in Patients With AML Undergoing HSCT Through Next-Generation Sequencing of T Cell Receptor Alpha (TCRA) and T Cell Receptor Beta (TCRB) Genes
University of Southern California · NCT03921047
This study is trying to see how the immune system's T-cells change in people with acute myeloid leukemia who are getting a stem cell transplant, by looking at blood samples before and after the procedure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Southern California (other) |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT03921047 on ClinicalTrials.gov |
What this trial studies
This research focuses on characterizing the T-cell receptor repertoire in patients with acute myeloid leukemia (AML) who are scheduled to undergo hematologic stem cell transplantation (HSCT). The study involves collecting blood samples from patients before, on day 100, and one year after the transplant, as well as from donors at the time of HSCT. The goal is to understand the immune system's role in high-risk AML patients by identifying molecular changes that shape the T-cell repertoire through next-generation sequencing.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with acute myeloid leukemia who are scheduled to undergo stem cell transplantation.
Not a fit: Patients who are unable to provide consent due to severe mental disorders or whose donors are unwilling to provide consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of the immune response in AML patients, potentially leading to improved treatment strategies.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in understanding T-cell dynamics in other hematological malignancies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of AML scheduled to undergo HSCT at University of Southern California (USC) Exclusion Criteria: * Inability to provide consent because of severe mental disorders * Donor unwilling to provide consent
Where this trial is running
Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States (RECRUITING)
Study contacts
- Principal investigator: Houda Alachkar, PharmD, PhD — University of Southern California
- Study coordinator: Christine Duran
- Email: Duran_C@med.usc.edu
- Phone: 323-865-0371
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Myeloid Leukemia